Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bakris

Showing results (601-610 of 738) with videos related to

Pageof 74
Sort By:
Circulation. Heart Failure|January 28, 2010
Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studiesC Barrett Bowling, Bertram Pitt, Mustafa I Ahmed, et al.
Circulation|June 27, 2018
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney FunctionBrendon L Neuen, Toshiaki Ohkuma, Bruce Neal, et al.
European Heart Journal|November 13, 2012
Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosisDharam J Kumbhani, P Gabriel Steg, Christopher P Cannon, et al.
Annals of Internal Medicine|December 4, 2023
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation AnalysisRajiv Agarwal, Wanzhu Tu, Alfredo E Farjat, et al.
JAMA Cardiology|June 14, 2023
Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With FinerenoneRajiv Agarwal, Bertram Pitt, Peter Rossing, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|April 25, 2007
Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINIV Fonseca, G L Bakris, D S H Bell, et al.
Circulation|March 26, 2008
N-terminal prohormone brain natriuretic peptide as a predictor of cardiovascular disease and mortality in blacks with hypertensive kidney disease: the African American Study of Kidney Disease and Hypertension (AASK)B C Astor, S Yi, L Hiremath, et al.
International Journal of Cardiology|November 6, 2012
The past, present and future of renin-angiotensin aldosterone system inhibitionRobert J Mentz, George L Bakris, Bernard Waeber, et al.
Diabetes, Obesity & Metabolism|August 14, 2023
Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trialsHiddo J L Heerspink, Priya Vart, Niels Jongs, et al.
Diabetes Care|July 29, 2025
Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary AnalysisPeter Rossing, George Bakris, Vlado Perkovic, et al.
Pageof 74

Showing results (601-610 of 738) with videos related to

Sort By:
Pageof 74
Circulation. Heart Failure|January 28, 2010
Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studiesC Barrett Bowling, Bertram Pitt, Mustafa I Ahmed, et al.
Circulation|June 27, 2018
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney FunctionBrendon L Neuen, Toshiaki Ohkuma, Bruce Neal, et al.
European Heart Journal|November 13, 2012
Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosisDharam J Kumbhani, P Gabriel Steg, Christopher P Cannon, et al.
Annals of Internal Medicine|December 4, 2023
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation AnalysisRajiv Agarwal, Wanzhu Tu, Alfredo E Farjat, et al.
JAMA Cardiology|June 14, 2023
Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With FinerenoneRajiv Agarwal, Bertram Pitt, Peter Rossing, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|April 25, 2007
Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINIV Fonseca, G L Bakris, D S H Bell, et al.
Circulation|March 26, 2008
N-terminal prohormone brain natriuretic peptide as a predictor of cardiovascular disease and mortality in blacks with hypertensive kidney disease: the African American Study of Kidney Disease and Hypertension (AASK)B C Astor, S Yi, L Hiremath, et al.
International Journal of Cardiology|November 6, 2012
The past, present and future of renin-angiotensin aldosterone system inhibitionRobert J Mentz, George L Bakris, Bernard Waeber, et al.
Diabetes, Obesity & Metabolism|August 14, 2023
Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trialsHiddo J L Heerspink, Priya Vart, Niels Jongs, et al.
Diabetes Care|July 29, 2025
Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary AnalysisPeter Rossing, George Bakris, Vlado Perkovic, et al.
Pageof 74